| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
symptom severity and performance on three timed tests of cognitive function were also measured prior to clozapine treatment in the schizophrenia group, and these measures were repeated during treatment with clozapine. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
treatment with clozapine was found to significantly improve reaction time and the accuracy of target detection in patients with schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
the results of this pilot study indicate that treatment with clozapine can produce limited improvement in cognitive function in schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
human leukocyte antigen-a1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
the authors have previously reported a significantly increased frequency of hla-a1 among patients with schizophrenia who do not respond to conventional drugs, but do respond to clozapine treatment. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
these results suggest that hla-a1 may predict a good therapeutic outcome and a low risk of agranulocytosis and, thus, enable defining a subgroup of patients with schizophrenia in whom clozapine treatment could be started early to stop the disease from progressing. |
2001-03-01 |
2023-08-12 |
human |
| M W Agelink, T Majewski, C Wurthmann, K Lukas, H Ullrich, T Linka, E Kliese. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199953. |
as part of a prospective clinical study investigating the effects of atypical neuroleptics on autonomic neurocardiac function (anf), serial standardized recordings of conventional electrocardiograms and computer-calculated measurements of 5-minute resting heart rate variability (hrv) were obtained from 51 medication-free inpatients with schizophrenia (dsm-iii-r-diagnosed) before and after an average of 14.1 days of treatment with amisulpride 400 mg/day (n = 12), olanzapine 20 mg/day (n = 13), sertindole 12 mg/day (n = 13), or clozapine 100 mg/day (n = 13). |
2001-03-01 |
2023-08-12 |
Not clear |
| K H Littrell, C G Johnson, N M Hilligoss, C D Peabody, S H Littrel. Switching clozapine responders to olanzapine. The Journal of clinical psychiatry. vol 61. issue 12. 2001-03-01. PMID:11206595. |
clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment. |
2001-03-01 |
2023-08-12 |
Not clear |
| M Dettling, C Sachse, J Brockmöller, J Schley, B Müller-Oerlinghausen, I Pickersgill, A Rolfs, R T Schaub, J Schmide. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology. vol 152. issue 1. 2001-02-15. PMID:11041319. |
clozapine is a unique antipsychotic drug, outstanding for its lack of extrapyramidal side-effects and its superior efficacy in refractory schizophrenia. |
2001-02-15 |
2023-08-12 |
Not clear |
| K Raaska, P J Neuvone. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European journal of clinical pharmacology. vol 56. issue 8. 2001-02-15. PMID:11151749. |
ciprofloxacin increases serum clozapine and n-desmethylclozapine: a study in patients with schizophrenia. |
2001-02-15 |
2023-08-12 |
Not clear |
| K Raaska, P J Neuvone. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European journal of clinical pharmacology. vol 56. issue 8. 2001-02-15. PMID:11151749. |
a possible pharmacokinetic interaction between a cyp1a2 inhibitor, ciprofloxacin, and clozapine was studied in schizophrenia patients with stable clozapine treatment. |
2001-02-15 |
2023-08-12 |
Not clear |
| K Wahlbeck, M Cheine, K Tuisku, A Ahokas, G Joffe, R Rimó. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 6. 2001-02-08. PMID:11041534. |
risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. |
2001-02-08 |
2023-08-12 |
human |
| K Wahlbeck, M Cheine, K Tuisku, A Ahokas, G Joffe, R Rimó. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 6. 2001-02-08. PMID:11041534. |
the atypical antipsychotic risperidone may constitute an alternative to clozapine, the current treatment of choice for refractory schizophrenia. |
2001-02-08 |
2023-08-12 |
human |
| C J Hong, Y W Yu, C H Lin, H L Song, H C Lai, K H Yang, S J Tsa. Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology. vol 42. issue 4. 2001-02-02. PMID:11096331. |
association study of apolipoprotein e epsilon4 with clinical phenotype and clozapine response in schizophrenia. |
2001-02-02 |
2023-08-12 |
Not clear |
| C J Hong, Y W Yu, C H Lin, H L Song, H C Lai, K H Yang, S J Tsa. Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology. vol 42. issue 4. 2001-02-02. PMID:11096331. |
the present study tested the hypothesis that the apoe epsilon4 allele confers association with the clinical manifestations of schizophrenia or clozapine response. |
2001-02-02 |
2023-08-12 |
Not clear |
| Dossenbach MRK, J N Beuzen, M Avnon, R H Belmaker, A Elizur, M Mark, H Munitz, M Schneidman, D Shoshani, P Kratky, S L Grundy, G D Tollefso. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clinical therapeutics. vol 22. issue 9. 2001-02-01. PMID:11048902. |
the effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. |
2001-02-01 |
2023-08-12 |
Not clear |
| Dossenbach MRK, J N Beuzen, M Avnon, R H Belmaker, A Elizur, M Mark, H Munitz, M Schneidman, D Shoshani, P Kratky, S L Grundy, G D Tollefso. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clinical therapeutics. vol 22. issue 9. 2001-02-01. PMID:11048902. |
this multicenter, open-label study was designed to assess the efficacy and tolerability of olanzapine in patients with chronic schizophrenia who are resistant to therapy with classic neuroleptic agents and are either not responsive to or unable to tolerate clozapine. |
2001-02-01 |
2023-08-12 |
Not clear |
| J A Cramer, R Rosenheck, W Xu, J Thomas, W Henderson, D S Charne. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophrenia bulletin. vol 26. issue 3. 2001-01-26. PMID:10993404. |
department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
2001-01-26 |
2023-08-12 |
Not clear |
| J A Cramer, R Rosenheck, W Xu, J Thomas, W Henderson, D S Charne. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophrenia bulletin. vol 26. issue 3. 2001-01-26. PMID:10993404. |
four hundred and twenty-three inpatients with schizophrenia participating in a clinical trial comparing clozapine and haloperidol (va cooperative study in health services #17) were evaluated using multiple measures of health-related quality of life (lehman quality of life interview; heinrichs-carpenter-hanlon quality of life scale; strauss-carpenter level of function scale, and clinical response.) |
2001-01-26 |
2023-08-12 |
Not clear |
| J P Lindenmaye. Treatment refractory schizophrenia. The Psychiatric quarterly. vol 71. issue 4. 2001-01-18. PMID:11025914. |
the effects of the atypicals clozapine, olanzapine, risperidone and quetiapine as compared to typicals are reviewed using available double-blind studies in this treatment refractory group of schizophrenia patients. |
2001-01-18 |
2023-08-12 |
Not clear |